This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Taking post #30 at face value and following it one step further.
Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
The confident version of this sentence would be wrong, so here is the hedged one.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
I would be glad to be shown a cleaner way of putting this.
Gastrointestinal effects in this class are dose-related and escalation-related. Both are true simultaneously, which is why symptoms typically return at each step and then settle again.
A single observation, in a thread that deserves better than single observations.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
I am not the right person to answer the follow-up to this.
Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.
The answer changed when I changed how I was measuring, which was informative.
I read post #34 twice before replying, because I had assumed the opposite.
Discontinuation for adverse effects in the published trials was not rare at the higher doses. That number belongs in any discussion of tolerability and is usually left out.
Coming back to post #39, because the follow-up matters more than the original answer.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
The claim is narrower than it sounds, and deliberately so.
Post #39 is right about the mechanism and I think understates the practical bit.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
If the premise is wrong, everything after it is decoration.
Reported effects on taste and on food preference are common and interesting and unstudied in any detail. They are also the ones people find most disconcerting.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Post #43 answers the question as asked. The question underneath it is different.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
If anyone can point at the primary source I would be grateful.
Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.
Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.
Reflux and eructation are the two most under-reported effects in the first-hand accounts here, and both follow directly from delayed emptying.
Not a strong opinion, just a consistent one.
This follows post #50 rather than contradicting it.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Worth separating two things that post #48 runs together.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
Adding a source would improve this post and I do not have one to hand.
Injection-site reactions are usually local, brief and unremarkable. A reaction spreading over a day, or accompanied by systemic symptoms, is a different thing and needs a clinician.
On post #52 — agreed on the reasoning, with one qualification.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
It is one reading of the data and not the only reasonable one.
Fine by me. I had wanted a stronger conclusion and there is not one available.
Tracking severity on a simple scale with dates is far more useful than describing it afterwards. Memory smooths a symptom curve into a story that fits what you expected.